Australia markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.9000+0.0400 (+2.15%)
At close: 04:00PM EDT
1.8100 -0.09 (-4.74%)
After hours: 05:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.8600
Open1.9100
Bid1.4500 x 3000
Ask2.0900 x 1400
Day's range1.9000 - 1.9900
52-week range1.3720 - 16.8000
Volume8,158
Avg. volume35,077
Market cap6.352M
Beta (5Y monthly)0.40
PE ratio (TTM)N/A
EPS (TTM)-2.3600
Earnings date08 May 2023 - 12 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.00
  • GlobeNewswire

    Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023

    Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI Image 1 All-Cause HCRU in the Pre-nasal MCP period vs. Post-nasal MCP period Image 2 Nausea, Vomiting, and DGP-associated HCRU in the Pre-nasal MCP period vs. Post-nasal MCP Period SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclo

  • GlobeNewswire

    Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

    Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31,

  • GlobeNewswire

    Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023

    SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes. Management will host a conference call on Tuesday, March 21, 2023, at 4:30 p.m. ET